Cutting Gel claims false and unsubstantiated...
The Federal Trade Commission has charged the makers of cutting
gel with making numerous false and unsubstantiated claims their
products.
The complaint focuses on six of the respondents’ heavily promoted
products, including Dermalin, Cutting Gel, and Tummy Flattening
Gel, Leptoprin and Anorex, and PediaLean.
The Federal Trade Commission alleges that the company made unsubstantiated
fat and weight loss claims, false claims that clinical testing proves
certain efficacy claims, and false claims that Daniel B. Mowrey,
Ph.D, is a medical doctor.
Dermalin, Cutting Gel, and Tummy Flattening Gel all contain the
active ingredient aminophylline in a lecithin base. Dermalin and
Tummy Flattening Gel are sold under the Klein-Becker USA and Sovage
trade names, and are advertised primarily to women interested in
thinning their figures.
Cutting Gel, sold under the Nutrasport trade name, is primarily
advertised to male bodybuilders who want to eliminate areas of fat
that obscure muscle definition.
The complaint challenges as unsubstantiated claims that Dermalin,
Cutting Gel, and Tummy Flattening Gel cause rapid and visibly obvious
fat loss in areas of the body to which they are applied.
The complaint challenges as false the claim that published, clinical
testing proves that Cutting Gel and Tummy Flattening Gel cause rapid
and visibly obvious fat loss in areas of the body to which they
are applied.
The complaint further challenges as unsubstantiated claims that
Leptoprin and Anorex cause weight loss of more than 20 pounds in
significantly overweight users and that those products cause loss
of substantial, excess fat in significantly overweight users.
In addition, the complaint challenges as false claims that clinical
testing proves that Leptoprin causes weight loss of more than 20
pounds, including as much as 50, 60, or 147 pounds, in significantly
overweight users; and that clinical testing proves that Leptoprin
causes loss of substantial, excess fat in significantly overweight
users.
In addition, the complaint challenges claims that PediaLean causes
substantial weight loss in overweight or obese children, and that
clinical testing proves such claims. The complaint further challenges
the respondents’ claim that respondent Mowrey is a medical
doctor. The Federal Trade Commission alleges that he is not.
Reference
Federal Trade Commission File No. 002-3300
http://www.ftc.gov/opa/2004/06/dietsupp.htm
|